• 1. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327

Introduction to 1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (CAS No. 2384171-56-4)

1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid (CAS No. 2384171-56-4) is a specialized heterocyclic compound that has garnered significant attention in the field of pharmaceutical and agrochemical research due to its unique structural properties and potential biological activities. This compound belongs to the pyrazole class, which is well-documented for its broad spectrum of pharmacological effects, including anti-inflammatory, antimicrobial, and anticancer properties. The presence of both cyclopropyl and trifluoromethyl substituents in its molecular framework enhances its pharmacokinetic profile, making it a promising candidate for further development.

The cyclopropyl group, characterized by its three-membered ring structure, introduces steric hindrance that can influence the compound's binding affinity to biological targets. This feature is particularly valuable in drug design, as it can optimize interactions with enzymes and receptors. On the other hand, the trifluoromethyl group, known for its electron-withdrawing properties, can modulate the metabolic stability and lipophilicity of the molecule, thereby affecting its overall bioavailability. These structural elements collectively contribute to the compound's potential as a lead molecule in medicinal chemistry.

In recent years, there has been a surge in research focused on developing novel therapeutic agents derived from pyrazole derivatives. The structural versatility of pyrazoles allows for the synthesis of a wide range of analogs with tailored biological activities. Specifically, 1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid has been studied for its potential role in inhibiting various enzymatic pathways associated with inflammation and cancer progression. Preliminary in vitro studies have demonstrated its ability to modulate key signaling pathways such as NF-κB and MAPK, which are central to many pathological processes.

The trifluoromethyl substituent plays a crucial role in enhancing the metabolic stability of the compound by resisting oxidative degradation. This property is particularly advantageous in drug development, as it extends the half-life of the molecule within the body, potentially improving therapeutic efficacy. Additionally, the cyclopropyl group's steric bulk can prevent unwanted interactions with off-target proteins, thereby reducing side effects. These characteristics make 1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid a compelling candidate for further investigation.

Advances in synthetic methodologies have enabled more efficient production of complex pyrazole derivatives like this compound. Modern techniques such as transition-metal-catalyzed cross-coupling reactions and microwave-assisted synthesis have significantly reduced reaction times and improved yields. These innovations are critical for scaling up production and facilitating preclinical and clinical trials. The ability to synthesize 1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid with high purity and consistency is essential for rigorous testing in biological models.

The pharmacological potential of this compound has been explored in several disease models. For instance, studies have indicated that it may exhibit anti-inflammatory effects by inhibiting COX-2 and LOX enzymes, which are key mediators of inflammation. Furthermore, its ability to interact with DNA-binding proteins has raised interest in its potential applications in oncology research. The cyclopropyl moiety's influence on binding affinity suggests that it could be engineered to target specific oncogenic pathways more effectively than existing chemotherapeutic agents.

Recent publications highlight the importance of structure-activity relationships (SARs) in optimizing pyrazole-based drugs. By systematically modifying substituents such as trifluoromethyl and cyclopropyl, researchers can fine-tune the biological activity of these compounds. Computational modeling techniques have also been employed to predict binding affinities and optimize molecular geometry before experimental synthesis. These approaches accelerate the drug discovery process by minimizing trial-and-error experimentation.

The agrochemical sector has also shown interest in pyrazole derivatives due to their potential as pesticides or herbicides. The unique combination of substituents in 1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid may confer properties such as enhanced photostability and soil persistence, making it suitable for agricultural applications. Such developments could contribute to sustainable farming practices by providing effective alternatives to traditional agrochemicals.

In conclusion,1-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid represents a significant advancement in heterocyclic chemistry with broad implications for pharmaceutical and agrochemical innovation. Its structural features offer a balance between biological activity and pharmacokinetic properties, making it an attractive scaffold for further exploration. Continued research into this compound will likely yield valuable insights into disease mechanisms and novel therapeutic strategies.

• 1822853-20-2(1-(2-methoxyethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid)
• 2137816-61-4(5-(difluoromethyl)-1-ethyl-1H-pyrazole-3-carboxylic acid)
• 2092336-57-5(1-(2-Methoxyethyl)-5-(trifluoromethyl)-1h-pyrazole-3-carboxylic acid)
• 2171990-19-3(3-(difluoromethyl)-1-(propan-2-yl)-1H-pyrazole-5-carboxylic acid)
• 1004643-70-2(1-ethyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid)
• 1006462-23-2(1-(2,2-Difluoroethyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic Acid)
• 1639115-35-7(ethyl 2-cyclopropyl-5-(trifluoromethyl)pyrazole-3-carboxylate)
• 128694-72-4(1-isopropyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid)
• 2137639-79-1(5-(difluoromethyl)-1-(propan-2-yl)-1H-pyrazole-3-carboxylic acid)
• 128694-66-6(1-Ethyl-3-(trifluoromethyl)-1H-pyrazole-5-carboxylic acid)